Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva
Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety signals reported for autoimmune disease cell therapy programs from Novartis and Bristol Myers Squibb.
ClarityCare Raises $16.5M to Speed Up Prior Authorizations
As health plans grapple with new federal deadlines for prior authorization decisions, healthcare AI startup ClarityCare has raised $16.5 million to automate the administrative workload that can keep patients waiting for the care they need.
A Market, Not a Mandate, Is the Fastest Way to Bring AI Into Hospitals
The cost of waiting is not evenly distributed. Rural and critical access hospitals report under 50 percent adoption of even basic predictive tools, compared with 86 percent among top-tier system-affiliated hospitals. Every year without a bridge widens that gap, and it widens it fastest for the hospitals with the least room to absorb it.
How Experts Are Reacting to Trump’s Women’s Health Executive Order
Women’s health experts had mixed reactions to the Trump administration's executive order on women's health.
Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3
Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech plans to start a Phase 3 trial.